Literature DB >> 9041323

The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies.

K Schoppel1, B Kropff, C Schmidt, R Vornhagen, M Mach.   

Abstract

An individual analysis of IgG antibodies against 12 known antigenic domains of human cytomegalovirus (HCMV)-derived structural phospho- and glycoproteins and nonstructural polypeptides was performed. In HCMV-seropositive healthy persons, the separate determination of antibody titers against the various antigens resulted in an antibody profile that was characteristic for each individual. Profiles were qualitatively stable over a period of >4 years. However, quantitative changes were observed in some persons. During primary HCMV infection, a delay of 50-100 days in the appearance of glycoprotein-specific antibodies was observed, whereas immunoglobulins directed against other HCMV-specific antigens were promptly synthesized. In contrast, during reactivation or reinfection, a synchronized production of antibodies was found. Levels of glycoprotein-specific antibodies and detection of viral DNA in peripheral blood inversely correlated. Precursor B cell analyses showed no significant differences between glycoprotein-specific and phosphoprotein-specific B cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041323     DOI: 10.1093/infdis/175.3.533

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay.

Authors:  Lutz Von Müller; Walter Hampl; Joachim Hinz; Helga Meisel; Angela Reip; Elisabeth Engelmann; Regine Heilbronn; Barbara Gärtner; Oliver Krämer; Hermann Einsele; Holger Hebart; Tatjana Ljubicic; Jürgen Löffler; Thomas Mertens
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Evaluation of a cytomegalovirus glycoprotein B recombinant enzyme immunoassay to discriminate between a recent and a past infection.

Authors:  M J Sipewa; P Goubau; M Bodéus
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 4.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

Review 5.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

6.  Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.

Authors:  Nina Reuter; Barbara Kropff; Julia Karin Schneiderbanger; Mira Alt; Adalbert Krawczyk; Christian Sinzger; Thomas H Winkler; William J Britt; Michael Mach; Marco Thomas
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

7.  Overview of the diagnosis of cytomegalovirus infection.

Authors:  S A Ross; Z Novak; S Pati; S B Boppana
Journal:  Infect Disord Drug Targets       Date:  2011-10

8.  Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus.

Authors:  Nadja Spindler; Pia Rücker; Sonja Pötzsch; Uschi Diestel; Heinrich Sticht; Luis Martin-Parras; Thomas H Winkler; Michael Mach
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

9.  Reactivity to p52 and CM2 recombinant proteins in primary human cytomegalovirus infection with a microparticle agglutination assay.

Authors:  E Nulens; M Bodéus; F Bonelli; A Soleti; P Goubau
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

10.  Strain-specific neutralization of human cytomegalovirus isolates by human sera.

Authors:  M Klein; K Schoppel; N Amvrossiadis; M Mach
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.